|
| Henry G. Grabowski, Professor Emeritus and Director of Program in Pharmaceutical Health Economics
 Henry G. Grabowski has been a professor in the department of economics at Duke University since 1976. The same year he became a full professor, he also served as a research fellow at the International Institute of Management. Before first joining the Duke faculty in 1972, he was a research associate for the National Bureau of Economic Research, an assistant professor of economics at Yale University, and a visiting scholar at the Health Care Financing Administration. Professor Grabowski earned his Ph.D. in economics in 1967 from Princeton University, where he also earned his M.A. in 1964.
Professor Grabowski’s teaching and research interests revolve around the economics of the pharmaceutical industry, the economics of innovation, and governmental regulation of business. His research studies have examined government policy actions and their effects on the pharmaceutical industry, costs and returns to the industry, and issues involving generic competition and intellectual property. Some of his recent published works include, “Follow-on Biologics: Data exclusivity and the Balance Between Innovations and Competition”, “Do Faster FDA Drug Reviews Adversely Affect patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act” with Richard Wang, and “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity” with Margaret Kyle. He has published over seventy-five articles in the leading academic journals and provided chapters to nearly thirty books.
Along with publishing his work, Professor Grabowski publicizes his research findings and ideas through presentations given nationally and internationally. He has been invited to speak at Columbia University, Georgetown University, Keio University in Tokyo, the American Economic Association meetings in Washington, D.C., the American Association for Advancement in Science in Boston, the University of Vienna, the Centre for Medicines Research Annual Lecture in London, and to many other prestigious universities and conventions.
Professor Grabowski holds various professional positions, in addition to his research and teaching responsibilities. At Duke University, he is the Director of the Program in Pharmaceuticals and Health Economics. He has also served as an advisor for various organizations, including the Institute of Medicine, the Federal Trade Commission, the National Academy of Sciences, the Office of Technology Assessment, and the General Accounting Office. He has also worked for the Arts and Sciences Council and for their Academic Priorities Committee. He was the program director for the Program in Pharmaceuticals and Health Economics for twenty years.
- Contact Info:
- Office Hours:
- By appointment
- Education:
| PhD | Princeton University | 1967 |
| M.A. | Princeton University | 1964 |
| B.S. | Lehigh University | 1962 |
- Specialties:
-
Econometrics
- Research Interests: Economics of Innovation, Governmental Regulation of Business, and Economics of Pharmaceutical Industry
Current projects:
Testimony and Public Policy Comments
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives to Innovate: An International Comparative Analysis” with John Vernon and Lacy Glenn Thomas, to his more recent projects including, “Impact of Economic, Regulatory and Patent Policies on Innovation in Cancer Chemoprevention” with Jeffrey L. Moe. His latest research studies include other such titles as, “Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R&D Productivity” with Margaret Kyle; “Should the Patent System for New Medicines Be Abolished?” with J.A. DiMasi; and several others. Professor Grabowski has served as an advisor and consultant to various organizations, offering his ideas and insights gained through his extensive investigations to the National Trade Academy of Sciences, the Institute of Medicine, the Office of Technology Assessment, the Federal Trade Commission, and the General Accounting Office. His latest project involved an analysis for the FTC concerning public policy, competition and investment in the “Next Generation of Biologics.”
- Curriculum Vitae
- Current Ph.D. Students
(Former Students)
- Postdocs Mentored
- David Ridley (2002/07-2003/07)
- Recent Publications
(More Publications)
- with Margaret Kyle, Richard Mortimer, Genia Long and Noam Kirson, Evolving Brand-Name and Generic Competition May Warrant a Revision of the Hatch-Waxman Act,
Health Affairs, vol. 30 no. 11
(November, 2011),
pp. 2157-2166 [PDF]
- The Evolution of the Pharmaceutical Industry Over the Past 50 Years: A Personal Reflection,
International Journal of the Economics of Business, vol. 18 no. 2
(July, 2011),
pp. 161-176 [PDF]
- with Genia Long and Richard Mortimer, Data Exclusivity for Biologics,
Nature Reviews Drug Discovery, vol. 10 no. 1
(January, 2011),
pp. 15-16 (PDF also includes the on-line supplementary material published in connection with this article..) [PDF]
- with Joseph DiMasi, R&D Costs and Returns,
in The Handbook of Pharmaceuticals, edited by OPatricia Danzon and Sean Nichols
(2011), Oxford University Press (Forthcoming.)
- with Genia long and Richard Mortimer, Implementation of the Biosimilar Pathway: Economic and Policy Issues,
Seton Hall Law Review, vol. 41 no. 2
(2011),
pp. 511-557 [PDF]
|
